Investigator Sponsored Studies
Vertex ISS grants fund investigator-led research advancing science and patient care in cystic fibrosis, sickle cell disease, beta thalassemia, IgA nephropathy, and pain.
Funder: Vertex Pharmaceuticals
Due Dates: Rolling (CF, Pain, IgA Nephropathy) | RFP-based (Beta Thalassemia, Sickle Cell Disease; currently closed)
Funding Amounts: No preset cap; budgets must represent fair market value and generally not exceed 35% institutional overhead.
Summary: Supports independent, investigator-led research advancing scientific knowledge in areas aligned with Vertex’s interests, including cystic fibrosis, sickle cell disease, IgA nephropathy, and pain.
Key Information: Funding is not available for retrospective/ongoing work, FTE-based personnel costs, or travel.
Description
Vertex Pharmaceuticals' Investigator Sponsored Studies (ISS) program provides funding for independent, investigator-initiated research that advances scientific understanding and patient care in disease areas of interest to Vertex. The program welcomes a range of clinical, observational, and nonclinical studies, particularly those exploring disease mechanisms, patient populations, and medical treatments relevant to Vertex’s portfolio. Supported research areas include cystic fibrosis, sickle cell disease, beta thalassemia, IgA nephropathy, and pain (US only). The ISS program is designed to foster collaboration with leading researchers and clinicians who share Vertex’s commitment to improving outcomes for people living with serious diseases.
